88 related articles for article (PubMed ID: 1788812)
1. [The effect of different programs of cytostatic therapy on the blood coagulation and rheological properties in multiple myeloma patients].
Katsadze IuL; Bessmel'tsev SS; Abdulkadyrov KM
Ter Arkh; 1991; 63(7):61-4. PubMed ID: 1788812
[TBL] [Abstract][Full Text] [Related]
2. [Immunological and rheological disorders in multiple myeloma patients].
Abdulkadyrov KM; Bessmel'tsev SS; Liubimova NIu
Ter Arkh; 1991; 63(7):122-6. PubMed ID: 1788790
[TBL] [Abstract][Full Text] [Related]
3. [Changes of electrocoagulographic parameters and erythrocyte deformability in multiple myeloma patients on various regimens of polychemotherapy].
Bessmel'tsev SS; Katsadze IuL
Klin Med (Mosk); 1991 Nov; 69(11):69-73. PubMed ID: 1808414
[TBL] [Abstract][Full Text] [Related]
4. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
5. [Four cases of therapy-related leukemia in multiple myeloma].
Natori K; Izumi H; Kaneko K; Ishihara S; Nagase D; Fujimoto Y; Kato M; Umeda M; Kuraishi Y
Gan To Kagaku Ryoho; 2007 Jan; 34(1):121-4. PubMed ID: 17220686
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy of polychemotherapy programs in treating multiple myeloma patients].
Bessmel'tsev SS; Abdulkadyrov KM; Rukavitsyn OA
Ter Arkh; 1998; 70(7):46-9. PubMed ID: 9742636
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
[TBL] [Abstract][Full Text] [Related]
8. Hyperammonemia after high-dose chemotherapy and stem cell transplantation.
Frere P; Canivet JL; Gennigens C; Rebeix JP; Fillet G; Beguin Y
Bone Marrow Transplant; 2000 Aug; 26(3):343-5. PubMed ID: 10967577
[TBL] [Abstract][Full Text] [Related]
9. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy with melphalan, cyclophosphamide, vincristine, ACNU and prednisolone (MEV(Ac)P) for multiple myeloma].
Takagi T; Oguro M; Sakai C
Rinsho Ketsueki; 1986 Dec; 27(12):2249-53. PubMed ID: 3471977
[No Abstract] [Full Text] [Related]
12. [Treatment of plasmacytoma with hyperviscosity syndrome].
Bosselmann HP; Gaede B; Franke A; Lachhein L
Z Gesamte Inn Med; 1988 May; 43(10):271-3. PubMed ID: 3414142
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
[TBL] [Abstract][Full Text] [Related]
14. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
[No Abstract] [Full Text] [Related]
15. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
[No Abstract] [Full Text] [Related]
16. [Comparative studies of intermittent melphalan and prednisolone (MP) versus 5-drug regimen (QUVMP) and 3-drug regimen (QUP) in multiple myeloma].
Hoshino S; Saito H; Wada M; Akutsu M; Shiozaki H; Takanashi M; Takei Y; Tanaka S; Teramura M; Takada K
Rinsho Ketsueki; 1987 Mar; 28(3):358-65. PubMed ID: 3475485
[No Abstract] [Full Text] [Related]
17. [Combination chemotherapy of multiple myeloma].
Uzuka Y; Saito Y; Ito T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944
[TBL] [Abstract][Full Text] [Related]
18. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
[TBL] [Abstract][Full Text] [Related]
19. Improved survival in multiple myeloma with combination chemotherapy and plasmapheresis.
Wahlin A; Holm J; Nyström L
Haematologia (Budap); 1984; 17(4):465-71. PubMed ID: 6532916
[TBL] [Abstract][Full Text] [Related]
20. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]